TESARO is an oncology-focused biopharmaceutical company.
TESARO is dedicated to improving the lives of cancer patients by developing and providing safer and more effective therapeutics and supportive care products.
Contact
TESARO Bio GmbH.
Poststrasse 6
6300 ZUG
Switzerland
| www.tesarobio.com
|
Benjamin Rousselot of Swiss ear hygiene specialists Laboratoires Diepharmex discusses the history of the company, new products, and the pros and cons of ‘Swissness’. Laboratoires Diepharmex is a Swiss-based, family…
Benjamin Rousselot of Swiss ear hygiene specialists Laboratoires Diepharmex discusses the history of the company, new products, and the pros and cons of ‘Swissness’. Laboratoires Diepharmex is a Swiss-based, family…
Jean-François Gouzer, CEO of Scientis Pharma, discusses the company’s origin story, its specialization in skin pigmentation disorders, and future internationalization prospects Could you start by introducing the Scientis Pharma story…
Jeff Dufour, country manager Switzerland and BU lead Internal Medicine at Pfizer, discusses his first impressions of the country, his priorities for greater dialogue with Swiss healthcare insurers, and Switzerland’s…
Petra Doerr, head of sector communication & networking as well as deputy executive director of Swissmedic, the Swiss surveillance authority for medicines and medical devices, discusses changes to the Swiss regulatory system…
Ryad Dahmani, CEO of Swiss-headquartered cold chain logistics specialists, Cold Chain Vision, discusses the impact of new technology in the logistics industry, the importance of quality controls in the transportation…
Stefan Frefel, CEO of Bilfinger Industrial Services in Switzerland, outlines Bilfinger’s core offering of maintenance and engineering services to the pharmaceutical industry, the importance of the Swiss affiliate to the…
Jonathan Koch, group president R&D Laboratories at Swiss-based CRO, Covance, explains how the integration process with LabCorb has progressed over the last two years, Covance’s embrace of digitally disruptive technologies,…
Marc Funk, COO of Swiss-headquartered product development service specialist, Lonza, discusses the company’s remarkable recent fortunes, how it is implementing innovative efficiency improvements, and answers the question, “why Switzerland?” …
In an exclusive interview, Bruno Strigini, global CEO of Novartis Oncology, discusses the logic of the company’s separate oncology business unit, the significance of US FDA approval for the new…
Oliver Rinner, CEO and founder of Biognosys, provides a fascinating account of the company’s unique business model and explains how its technical research into proteomics and cell expression is likely…
Marina Lugova, executive VP Business Development at API manufacturer Synbias Pharma, discusses why Switzerland was chosen as the company’s headquarters, Synbias’s internationalization strategy, and why it is the partner of…
See our Cookie Privacy Policy Here
